609 related articles for article (PubMed ID: 24297863)
21. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
22. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
23. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.
Bid HK; Phelps DA; Xaio L; Guttridge DC; Lin J; London C; Baker LH; Mo X; Houghton PJ
Mol Cancer Ther; 2016 May; 15(5):1018-28. PubMed ID: 26908627
[TBL] [Abstract][Full Text] [Related]
24. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
25. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
29. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
30. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
31. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP
Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878
[TBL] [Abstract][Full Text] [Related]
33. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
[TBL] [Abstract][Full Text] [Related]
34. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
[TBL] [Abstract][Full Text] [Related]
35. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
36. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
37. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
38. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
39. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
40. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
